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Abstract
A case of malignant mesenchymoma of the bladder containing leiomyosarcoma, rhabdomyosarcoma,
chondrosarcoma, osteosarcoma, and myxomatous components is described. The primary pedunculated tumor
measuring 14 × 13 × 7 cm and weighing 343 g arose from the left trigone of the bladder and was treated by
total cystectomy. The histogenesis of malignant mesenchymomas and their optimal management strategy and
prognosis remain uncertain. Herein, we present the fifth case of malignant mesenchymoma of the urinary bladder
to be reported in the literature, which presented five unrelated differentiated tissues more than did previously
reported cases.
Background
Malignant mesenchymoma, which was described by
S t o u ti n1 9 4 8 ,i sd e f i n e da sam a l i g n a n ts o f tt i s s u e
tumor that consists of two or more distinctly different
mesenchymal components in addition to fibrosarcoma-
tous elements. A review of the literature revealed only
four cases of bladder sarcomas that fit the criteria.
Case presentation
A 77-year-old Taiwanese man had a multiyear history of
symptoms of micturition difficulty. Gross hematuria
with severe pain had developed suddenly in the previous
month. The patient is a retired military soldier had
neither history of cigarette smoking nor habbit of alco-
hol comsumption. He had a history of hypertension and
type II diabetes mellitus for 20 years controlled with
regular medication. He didn’t exposures to paint compo-
nents or eat undercooked meat. There is no specific ill-
ness could be traced from the patient’s family pedigree.
On physical examination, the patient appeared to be
recently poorly nourished and had normal vital signs
and mild elevated blood pressure at 151/88 mmHg. His
lungs were clear, heart sounds were normal, and the
abdomen was soft, with no masses and no tenderness.
There was no edema of the legs. In laboratory data, the
results of a complete blood count and the levels of elec-
trolytes were normal. However, serum total protein,
albumin, creatinine (Cr), urea nitrogen (BUN), and
glucose were abnormal and showing hypoproteinemia
(5.5 g/dL), hypoalbuminemia (3.0 g/dL), abnormal renal
function with moderate azotemia (BUN/Cr = 36/1.3),
and hyperglycemia (179 g/dL).
Real-time sonographic evaluation of the abdomen
showed increased echogenicity of bilateral kidneys. The
sizes of the kidneys were 9 cm on the right and 10.3 cm
on the left. Mild dilatation of left renal pelvis is also
noted. Furthermore, one lobulated mass with urinary
bladder wall thickening was also identified.
Magnetic resonance imaging (MRI) of the pelvis demon-
strated a large mass in the urinary bladder. The mass
shows focal contrast medium enhancement on the left
side with adjacent vesical wall thickening and obliteration
of the lower signal intensity on T2WI (Figure 1A). Urinary
bladder malignancy was suspected, and the differential
diagnoses included urothelial cell carcinoma with blood
clot, sarcoma, or other benign neoplastic mass.
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was performed. Pathological examination led to a diagno-
sis of high-grade sarcoma composed of myofibrous differ-
entiation, focal myxomatous pattern, and a few chondroid
changes with marked nuclear atypia and increased mitotic
figures (more than 10/10 high power field). Radical
cystectomy was performed. The patient currently remains
well and prepares to undergo adjuvant chemotherapy.
Results
Macroscopically, the urinary bladder contained a none-
ncapsulated, huge, and lobular mass, which was located
in the left trigone and measured 14 × 13 × 7 cm. On its
cut surface, this tumor was composed of a predominant
white, myofibrous-like component (70%), with myxoma-
tous (20%), hemorrhage, and tumor necrosis (7%) foci.
Several hard osteochondroid-like nodules were also
Figure 1 (A) Magnetic resonance imaging (MRI) of the pelvis demonstrated a large mass in the urinary bladder that shows focal
contrast medium enhancement on the left side with adjacent vesical wall thickening and obliteration of the lower signal intensity on
T2WI. (B) Macroscopically, the urinary bladder contained a nonencapsulated, huge, and lobular mass, which was located in the left trigone and
measured 14 × 13 × 7 cm in size. (C) and (D) On the cut surface, this tumor was composed of a predominant white, myofibrous-like
component, and myxomatous (asterisk), hemorrhage, and tumor necrosis foci. Several hard osteochondroid-like nodules were also palpable
within this tumor (arrow).
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tumor lesion (Figure 1B, C, and 1D).
Microscopically, the tumor cells exhibited pleo-
morphic spindle tumor cells composed of predominant
myofibrous differentiation with focal rhabdoid, chon-
droid, osteoid, and focal myxomatous differentiation.
Nuclear atypia, focal clear cytoplasm, marked increased
mitotic figures, focal hemorrhage, and tumor necrosis
are also noted (Figure 2). The spindle tumor cells
showed focally positive immunoreactivity to smooth
muscle actin, calponin, and myoglobulin antibodies
(Figure 3A, B, and S3C). This tumor also shows very
high proliferative activity through Ki-67 immunohisto-
chemical staining (Figure 3D). Immunohistochemical
findings are summarized in Table 1. No epithelial com-
ponent was seen. The surgical margins were all free of
tumor cells. Lymphovascular space invasion was not
identified. According to the clinical information, histo-
pathological features, and immunoprofiles, it was a case
of malignant mesenchymoma, and the AJCC sarcoma
staging was pT2bN0M0, stage III.
Discussion
Primary sarcomas of the urinary bladder are uncommon
and mostly originate from muscle such as rhabdomyo-
sarcoma, which is dominant in children, or leiomyosar-
coma, which is dominant in adults. Other rare sarcomas
documented in the literature include primary osteosar-
coma (31 cases) [1], malignant fibrous histiocytoma
(30 cases) [2], primary angiosarcoma (15 cases) [3], and
several cases of malignant mesenchymoma.
Malignant mesenchymoma is the rarest sarcoma of the
urinary bladder, and it was defined by Stout as a sarcoma
comprising two or more unrelated differentiated tissue
elements other than a fibrosarcoma component. Our
case presents five unrelated differentiated tissues other
than fibrosarcoma. To our knowledge, in the English-lan-
guage medical literature, only four cases of malignant
mesenchymoma of the urinary bladder have been pre-
viously reported [4-7]. The major clinical and pathologi-
cal features of these cases and our case are summarized
in Table 2. The available data for malignant mesenchy-
moma of the urinary bladder show that it predominantly
occurs in male patients who are older than 40 years. The
highest incidence is in the eighth decade. The size of the
tumor is often more than 10 cm, and an advanced AJCC
sarcoma stage is common when diagnosed.
Malignant mesenchymoma can occur at all locations
in the body, including the retroperitoneum, soft tissue
of the lower limbs, heart [8], mediastinum [9], pleura
[10], liver [11], orbit [12], bone [13], larynx [14], thyroid
[15], testis [16], uterine [17], and urinary bladder [4-7].
Such tumors more frequently develop in the retroperito-
neum and the soft tissue of the lower limbs.
Figure 2 Microscopically, the tumor cells exhibited pleomorphic spindle tumor cells composed of (A) predominant myofibrous
differentiation, (B) rhabdoid with chondroid differentiation, (C) osteoid differentiation. Unlike metaplasia, neoplastic osteosarcoma cells
are usually surrounded by deposited osteoid material and (D) focal myxomatous differentiation (hematoxylin and eosin staining, ×200).
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nant mesenchymoma according to the definition, but
these are frequently treated as distinct and separate enti-
ties, such as malignant triton tumor, ectomesenchymoma,
dedifferentiated liposarcoma, and chondrosarcoma with a
second differentiated component [18].
Malignant mesenchymoma appears to arise from a
primitive mesenchymal cell with the capacity for totipo-
tent differentiation, but the histogenesis remains
uncertain.
One should be careful when diagnosing malignant
mesenchymoma, because some sarcomas are easily com-
bined with bone and chondroid metaplasia that could
mimic this diagnosis. The histological distinction
between neoplastic and metaplastic bone is based on the
pattern of the deposited bone, the cytological features of
the bone-forming cells, and the cellular composition of
the intratrabecular tissue. Metaplastic bone often has a
lamellar architecture, and it is usually organized around
areas of hemorrhage or portions of tumor. In contrast,
Figure 3 This high-grade sarcoma shows muscle differentiation because of focally positive immunoreactivity to (A) calponin, (B)
myoglobulin, and (C) smooth muscle actin antibodies. (D) It also expressed a high proliferation index by Ki-67 staining (×200).
Table 1 Immunohistochemical results for all kinds differentiated components of malignant mesenchymoma
Antibody Clone Dilution leiomyosarcoma rhabdomyosarcoma chondrosarcoma osteosarcoma
Cytokeratin-7 OV-TL12/30 1:500 Negative Negative Negative Negative
Cytokeratin-20 Ks 20.8 1:100 Negative Negative Negative Negative
Vimentin clone V9 1:200 Positive Positive Positive Positive
CD10 56C6 1:50 Positive Negative Negative Negative
CD34 QBEnd-10 1:100 Negative Negative Negative Negative
SMA* HHF35 1:75 Positive Positive Negative Negative
Calponin CALP 1:50 Positive Positive Negative Negative
Caldesmon h-CD 1:100 Negative Negative Negative Negative
Myoglobulin Lot 127 1:400 Positive Positive Negative Negative
Myo-D1 5.2F 1:100 Negative Negative Negative Negative
Myogenin F5D 1:100 Negative Negative Negative Negative
S100 4C4.9 1:100 Negative Negative Negative Negative
HMB-45 M0634 1:50 Negative Negative Negative Negative
*SMA, smooth muscle actin.
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deposited osteoid material (Figure 2C).
The prognosis of malignant mesenchymomas remains
controversial. Malignant mesenchymomas are commonly
accepted as high-grade malignant neoplasms. Bradythe
had reported two- and three-year survival rates of 75%
and 37%, respectively, in eight femoral and retroperito-
neal cases [19]. However, Newman and Fletcher sug-
gested low-grade malignant behavior for malignant
mesenchymoma bases in six cases, four of which had
less than five years of follow-up [20]. Adachi reported
that a patient aged under 40 years and the presence of a
rhabdomyosarcomatous component correspond to a
poor prognosis, but there is no significant prognosis dif-
ference with respect to gender, tumor site, tumor size,
or MIB-1-labeling index [21].
Because of its extreme rarity, there are insufficient
data to suggest the best modality or combination of
treatments for this condition [11,22,23]. Chemotherapy
a n dr a d i o t h e r a p yw e r ei n e f f e c t i v ef o rt h es o f tp a r t so f
the sarcoma, including the malignant mesenchymoma,
but the efficacy of chemotherapy with doxorubicin plus
ifosfamide and cyclophosphamide, vincristine, doxorubi-
cin, and dacarbazine has recently been reported. Thus, a
multidisciplinary approach including surgery, radiother-
apy, and chemotherapy may be useful for these tumors
[23].
Conclusions
In summary, malignant mesenchymoma is a rare tumor,
and this is the fifth reported case of a malignant
mesenchymoma of the urinary bladder. Because of the
limited experience with this extremely rare tumor, there
are insufficient data to suggest the optimal management
strategy and prognosis for malignant mesenchymoma of
the urinary bladder.
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